Posts by Mourabit Halima

With the rapid development of medical technology, modern lymphoma treatment has become a key focus in the field of oncology. From May 25 to 26, the Modern Lymphoma Treatment Academic Conference and the 5th International Lymphoma Radiation Oncology Group (ILROG) Continuing Education Annual Meeting were successfully held online. The conference featured thematic speeches, in-depth case analyses, and scientific experience exchanges, covering various subtypes including Hodgkin lymphoma, diffuse large B-cell lymphoma, indolent lymphoma, extranodal lymphoma, plasma cell myeloma, and more. Core topics focused on the application of high-tech, optimization strategies for radiation therapy, new treatment methods, precise classification, and diagnostic techniques, providing participants with valuable insights into the latest advancements and future trends in the field. Notably, the conference brought together many internationally renowned experts who provided in-depth analyses and interpretations of lymphoma guidelines, evidence-based medicine, and clinical practice, offering excellent academic references. Professor Shunan Qi from the Cancer Hospital of the Chinese Academy of Medical Sciences, representing the organizing unit of this conference, gave an exclusive interview to "Oncology Frontier - Hematology Frontier" to provide a detailed interpretation of the conference's exciting content and advancements.

From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was grandly held in Glasgow, UK, a city renowned for its historical significance. This year marks the 50th anniversary of EBMT, and the event gathered leading figures in the field of hematopoietic stem cell transplantation and over 6,000 hematology experts from around the world. The attendees reviewed the remarkable achievements in the fields of hematology and bone marrow transplantation over the past 50 years and explored forward-looking patient management strategies. At the conference, chimeric antigen receptor T-cell (CAR-T) therapy, a highlight of this meeting, showcased a series of breakthroughs in the treatment of multiple myeloma and lymphoma, attracting significant attention. This issue features a special invitation to Professor Jun Ma from the Harbin Institute of Hematological Oncology to provide an insightful interpretation of five major research studies in the field of CAR-T cell therapy. Here, we present a compilation of these insights for our readers.

The "2024 Nanjing Lymphoma Forum" was held in Nanjing from May 11-12, 2024. The conference, primarily conducted through in-person exchanges, invited renowned experts in the field of lymphoid tumors from both domestic and international arenas. Through lectures, case discussions, and other forms of interaction, the forum focused on the latest achievements and advancements in the basic and clinical aspects of international lymphoid tumors. The goal was to further enhance the overall level of lymphoma diagnosis and treatment in China. At the conference, Professor Donglu Zhao from the Harbin Hematology and Oncology Research Institute gave a detailed presentation on the "CSCO Lymphoma Diagnosis and Treatment Guidelines — Interpretation of the Key Points of the Burkitt Lymphoma Guidelines." For a deeper understanding of this topic, "Oncology Frontier - Hematology Frontier" has compiled the content for readers' reference.